<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.006</object-id><label>Table 2.</label><caption><p>Antibiogram of <italic>S. aureus</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.006">http://dx.doi.org/10.7554/eLife.18082.006</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n&#160;=&#160;1176 patients)</th><th valign="top">HCAB <break/>(n&#160;=&#160;259 patients)</th><th valign="top">HAB <break/>(n&#160;=&#160;446 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">24/484 (5%)</td><td valign="top">16/84 (19%)</td><td valign="top">66/151 (44%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ansamycins</td><td valign="top">Rifampin</td><td valign="top">2/129 (2%)</td><td valign="top">1/19 (5%)</td><td valign="top">0/38 (0%)</td><td valign="top">0.37</td></tr><tr><td valign="top">Anti-MRSA cephalosporins</td><td valign="top">Ceftaroline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Cefamycins</td><td valign="top">Oxacillin *</td><td valign="top">80/1145 (7%)</td><td valign="top">67/247 (27%)</td><td valign="top">210/441 (48%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">3/45 (7%)</td><td valign="top">2/8 (25%)</td><td valign="top">4/10 (40%)</td><td valign="top">0.01</td></tr><tr><td valign="top">Moxifloxacin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Folate pathway inhibitors</td><td valign="top">Trimethoprim-sulphamethoxazole</td><td valign="top">99/1139 (9%)</td><td valign="top">57/251 (23%)</td><td valign="top">185/438 (42%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Fucidanes</td><td valign="top">Fusidic acid</td><td valign="top">33/618 (5%)</td><td valign="top">4/170 (2%)</td><td valign="top">12/291 (4%)</td><td valign="top">0.26</td></tr><tr><td rowspan="3" valign="top">Glycopeptides</td><td valign="top">Vancomycin &#8224;</td><td valign="top">4/833 (0.5%)</td><td valign="top">0/190 (0%)</td><td valign="top">2/357 (1%)</td><td valign="top">0.86</td></tr><tr><td valign="top">Teicoplanin</td><td valign="top">2/66 (3%)</td><td valign="top">1/17 (6%)</td><td valign="top">0/17 (0%)</td><td valign="top">0.72</td></tr><tr><td valign="top">Telavancin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Lincosamides</td><td valign="top">Clindamycin</td><td valign="top">118/1147 (10%)</td><td valign="top">77/251 (31%)</td><td valign="top">202/438 (46%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Lipopeptides</td><td valign="top">Daptomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Macrolides</td><td valign="top">Erythromycin</td><td valign="top">138/1116 (12%)</td><td valign="top">76/240 (32%)</td><td valign="top">222/429 (52%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Oxazolidinones</td><td valign="top">Linezolid</td><td valign="top">0/81 (0%)</td><td valign="top">0/16 (0%)</td><td valign="top">0/32 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Phenicols</td><td valign="top">Chloramphenicol</td><td valign="top">6/86 (7%)</td><td valign="top">4/24 (17%)</td><td valign="top">2/14 (14%)</td><td valign="top">0.21</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">14/361 (4%)</td><td valign="top">10/66 (15%)</td><td valign="top">24/141 (17%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Streptogramins</td><td valign="top">Quinupristin-dalfopristin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Tetracyclines</td><td valign="top">Tetracycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Doxycycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Minocycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">94/1176 (8%)</td><td valign="top">73/259 (28%)</td><td valign="top">222/446 (50%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB&#160;=&#160;Community-acquired bacteraemia, HCAB&#160;=&#160;Healthcare-associated bacteraemia, HAB&#160;= Hospital-acquired bacteraemia, and NA&#160;=&#160;Not available. The first isolate of each patient was used. MDR (one or more of these have to apply): (i) an MRSA is always considered MDR by virtue of being an MRSA (ii) non-susceptible to &#8805;1 agent in &#8805;3 antimicrobial categories.</p></fn><fn id="tblfn3"><p>* Defined by using a 30 &#956;g cefoxitin disc and an inhibition zone diameter of &lt;21 mm.</p></fn><fn id="tblfn4"><p>&#8224; Defined by using a 30 &#956;g vancomycin disc and an inhibition zone diameter of &lt;15 mm.</p></fn></table-wrap-foot></table-wrap>